Alimera Sciences Inc  

(Public, NASDAQ:ALIM)   Watch this stock  
Find more results for ALIM
4.73
-0.04 (-0.84%)
Real-time:   9:44AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.73 - 4.79
52 week 3.98 - 6.54
Open 4.79
Vol / Avg. 3,760.00/93,320.00
Mkt cap 210.00M
P/E     -
Div/yield     -
EPS -0.53
Shares 44.40M
Beta 1.16
Inst. own 100%
Aug 10, 2015
Q2 2015 Alimera Sciences Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 10, 2015
Q2 2015 Alimera Sciences Inc Earnings Release - 4:00PM EDT - Add to calendar
Jul 8, 2015
Alimera Sciences Inc at Cantor Fitzgerald Inaugural Healthcare Conference
Jun 25, 2015
Alimera Sciences Inc Annual Shareholders Meeting
May 19, 2015
Alimera Sciences Inc at UBS Global Healthcare Conference
May 7, 2015
Q1 2015 Alimera Sciences Inc Earnings Call
May 7, 2015
Q1 2015 Alimera Sciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -248.68% -426.33%
Operating margin -279.18% -396.38%
EBITD margin - -383.33%
Return on average assets -38.09% -55.66%
Return on average equity - -
Employees 105 -
CDP Score - -

Address

6120 Windward Pkwy Ste 290
ALPHARETTA, GA 30005-8897
United States - Map
+1-678-9905740 (Phone)
+1-678-9905744 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company focuses on diseases affecting the back of the eye, or retina. The Company's commercial product is ILUVIEN, which has been developed to treat diabetic macular edema (DME). ILUVIEN has received marketing authorization in the United States, Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the EU countries, it is indicated for the treatment of vision impairment associated with DME.

Officers and directors

C. Daniel Myers President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Richard S. Eiswirth Jr. Chief Financial Officer, Chief Operating Officer
Age: 46
Bio & Compensation  - Reuters
Kenneth Green Ph.D. Senior Vice President, Chief Scientific Officer
Age: 56
Bio & Compensation  - Reuters
David R Holland Senior Vice President - Sales and Marketing
Age: 51
Bio & Compensation  - Reuters
Philip Ashman Senior Vice President, European Managing Director
Age: 50
Bio & Compensation  - Reuters
David Burke Vice President
Bio & Compensation  - Reuters
Mark J. Brooks Independent Director
Age: 48
Bio & Compensation  - Reuters
Brian K. Halak Ph.D. Independent Director
Bio & Compensation  - Reuters
James R. Largent Independent Director
Age: 65
Bio & Compensation  - Reuters
Peter J. Pizzo III Independent Director
Age: 48
Bio & Compensation  - Reuters